

PTO/SB/20 (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:
Commissioner for Patents
Box RCE
Washington, DC 20231

Application Number	09/599,152
Filing Date	June 21, 2000
First Named Inventor	Yang, David
Art Unit	1619
Examiner Name	Jones, Dameron
Attorney Docket Number	UTXC:664

17
7/23/03

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- iii. ☐ Other _____
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☒ Information Disclosure Statement (IDS)
- iv. ☒ Other Declaration filed 3/14/03 in SN 09/434,313

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(f) required)
- b. ☐ Other _____

3. Fees

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 50-1212/UTXC:664
- i. ☒ RCE fee required under 37 CFR 1.17(e)
- ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17)
- iii. ☐ Other _____
- b. ☐ Check in the amount of \$ _____ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	David L. Parker	Registration No. (Attorney/Agent)	32,165
Signature		Date	3/19/03

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	David L. Parker	Date	3/19/03
Signature			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

FAX RECEIVED

JUL 22 2003

GROUP 1600**OFFICIAL****FACSIMILE TRANSMISSION****DATE:** July 22, 2003**MATTER NUMBER:**

10020527

RECIPIENT:	FAX NO.:	PHONE NO.:
Examiner Jones	703-308-4556	703-308-4640

FROM: David L. Parker**USER ID:** DP01982 **FLOOR:** 20**PHONE:** (512) 536-3055**FAX:** (512) 536-4598**RE:** SN 09/599,152**NUMBER OF PAGES WITH COVER PAGE:** 62**Message:**

Per your request, enclosed is a copy of the RCE and accompanying documents we filed on March 19, 2003. Also enclosed is the stamped postcard showing receipt of these documents by the PTO on March 24, 2003.

If you need anything else, please feel free to contact me.

CAUTION - CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

**IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL
LORI BARNETT AT (512) 536-3073 AS SOON AS POSSIBLE.**

Please indicate receipt of the below-identified paper:

<input type="checkbox"/> New Application For:	Priority Date:
<input type="checkbox"/> Foreign priority already claimed	MM 7 4 2003
<input type="checkbox"/> Continuation	<input type="checkbox"/> Divisional
<input type="checkbox"/> Specification:	CPA <input type="checkbox"/>
<input type="checkbox"/> Response to Office Action Dated:	Pages: <input type="checkbox"/> Drawings: <input type="checkbox"/> Sheets: <input type="checkbox"/>
<input checked="" type="checkbox"/> Other: RCE; Response to Office Action; Request for Extension of Time; Declaration; Supplemental IDS (with form 1449 and references A13 and C146)	<input type="checkbox"/> Final Rejection
<input type="checkbox"/> Assignment Enclosed	<input checked="" type="checkbox"/> Cert. of Timely Mailing
	<input type="checkbox"/> Exp. Mail:

IDENTIFICATION OF APPLICATION

Serial No.: 09/599,152
Title: ETHYLENEDICISTEIN (EC)-DRUG CONJUGATES, COMPOSITIONS AND METHODS FOR TISSUE SPECIFIC DISEASE IMAGING
Applicant: Yang et al.
Client: M. D. Anderson Cancer Center
Mailed: 3/19/03
Filed:
Attorney: DLP
F&J File No.: UTXC:664
Due Date: 1/28/03